Company

Overview

Everist Genomics, Inc. (EGI) is a personalized medicine company which develops and commercializes proprietary, highly differentiated, diagnostics, prognostics and therapeutic selection technologies which assist physicians in making medically optimal and cost effective treatment decisions. The EGI portfolio of personalized medicine products successfully integrates wireless mobile technology, patent protected software and e-commerce solutions; creating highly innovative technology with recurring revenue streams. EGI is focused on rapidly growing disease areas with substantial unmet needs including cancer, cardiovascular disease, and metabolic disease (e.g. diabetes).

EGI is a closely held, privately owned company, headquartered in Ann Arbor, Michigan.  The principle shareholders of EGI are large family investment offices headquartered in Denver Colorado, Sioux Falls South Dakota, Manhattan New York and Naples Florida.

Dr. Prasad Sunkara serves as Chief Executive Officer and President of EGI.   Mr. Thomas Everist is Chairman of the Board of Directors. He also serves as the President and Chairman of The Everist Company, and is a member of the Board of Directors of MDU Resources Group, Inc., a Fortune 500 company primarily related to supporting energy and transportation infrastructure.

EGI was formed two years ago by combining the assets, product portfolios, capabilities and IP of Genetics Squared, Inc., Angiologix Inc. and MedicalAlgorithmics, S.A. Everist Genomics has successfully completed several cash-based company and product acquisitions, all financed by the current family office shareholder base.  EGI’s patent protected products aid physicians in:

1. Early diagnosis of diseases (such as cancer, cardiovascular disease and metabolic disease), long before there are any detectable symptoms and thereby enabling early and more effective treatment while also reducing healthcare costs and saving lives.
   
   Example of EGI products:
   
   AngioDefender: a non-invasive sensor technology device for the early diagnosis of atherosclerosis and cardiovascular disease years before a patient has detectable symptoms.
   
   CardioDefender, the world’s first smartphone based, real-time, beat-by-beat, quantitative heart arrhythmia monitor which enables physicians to monitor a patient’s heart rhythm and receive automated alerts from anywhere in the world.  The technology provides the quality of heart rhythm monitoring which has in the past been confined to the hospital setting utilizing proprietary software, algorithms, smartphone and Bluetooth technology.
2. Disease prognosis products identify individual patients at high-risk of experiencing a recurrence of a cancer for which they have been previously treated.  This enables physicians to administer adjuvant (chemo-radiation) therapy which improves disease free rates and reduces patient mortality.  This technology also saves the healthcare system money; adjuvant therapy costs just 20% of post cancer-recurrence treatment.
   
   Example of EGI product:  OncoDefender - CRC, a molecular diagnostic which predicts the risk of recurrence in patients previously treated for colorectal cancer by measuring gene expression levels that are highly accurate predictors of cancer recurrence.
3. Therapeutic selection tests which help physicians identify which therapeutics a patient’s disease is most likely to respond well to.  This is particularly important in cancer and infectious diseases where the specific type of tumor or infection a patient has will determine which drug will be the optimal treatment in terms of efficacy and safety.
   
   Example of EGI product – OncoSelector - 5FU, a molecular diagnostic test which helps physicians determine which colorectal cancer patients are likely to best respond to and tolerate the side-effects associated with the chemotherapeutic drug Fluorouracil (5FU)

International Joint-Venture Companies:
EGI commercializes their products globally; in India, China and Japan, EGI is establishing joint-venture companies with leading multi-national corporate partners to implement local manufacturing, marketing and sales.  In 2011 EGI established the first of these joint-venture companies in India with the Manipal Group, a leading multi-national healthcare company.